T1	Participants 363 449	patients with previously treated, PD-L1-positive, advanced non-small-cell lung cancer.
T2	Participants 513 557	202 academic medical centres in 24 countries
T3	Participants 559 671	Patients with previously treated non-small-cell lung cancer with PD-L1 expression on at least 1% of tumour cells
T4	Participants 1279 1345	Between Aug 28, 2013, and Feb 27, 2015, we enrolled 1034 patients:
